Premera Bluecross Atopic Dermatitis Coverage Update

Coverage Criteria and Agent-specific Requirements

Agent-specific initial coverage criteria

Covered when ALL of the following are met (per-agent criteria):

Vtama (tapinarof) topical: Individual is aged 2 years or older AND has had an inadequate response or intolerance to one topical corticosteroid medication (exception may be granted for face or genital involvement) AND has had an inadequate response or intolerance to one topical calcineurin inhibitor medication (e.g., pimecrolimus or tacrolimus).

Elidel (pimecrolimus) and Protopic (tacrolimus) topical: Individual is aged 2 years or older AND has had an inadequate response or intolerance to one topical corticosteroid medication (exception may be granted for face or genital involvement) AND has tried both generic pimecrolimus and generic tacrolimus first and had inadequate response or intolerance to both (documentation required).

Adbry (tralokinumab-Idrm) SC: Individual is aged 12 years or older AND has a diagnosis of atopic dermatitis involving at least 10% BSA (exceptions: extensive recalcitrant facial involvement, pustular hands/feet, or genital involvement interfering with sexual function) AND has had inadequate response or intolerance to one topical calcineurin inhibitor AND to one high-potency topical corticosteroid AND medication is prescribed by or in consultation with an allergist, immunologist, or dermatologist AND maintenance dose prescribed per product labeling (maintenance dose referenced in policy).

Ebglyss (lebrikizumab-Ibkz) SC: Individual is aged 12 years or older AND has a diagnosis of atopic dermatitis involving at least 10% BSA (same exceptions as above) AND has had inadequate response or intolerance to one topical calcineurin inhibitor AND to one high-potency topical corticosteroid AND medication is prescribed by or in consultation with an allergist, immunologist, or dermatologist AND maintenance dosing per product labeling.

Nemluvio (nemolizumab-ilto) SC: Individual is aged 12 years or older AND has a diagnosis of atopic dermatitis involving at least 10% BSA (exceptions allowed) AND has had inadequate response or intolerance to one topical calcineurin inhibitor AND to one high-potency topical corticosteroid AND has had inadequate response or intolerance to prior biologic or JAK agents (examples listed in policy) AND medication is prescribed by or in consultation with a specialist AND maintenance dosing limited per policy. Also may be considered for prurigo nodularis in adults meeting specified nodularity and pruritus criteria.

Cibinqo (abrocitinib) oral: Individual is aged 12 years or older AND has a diagnosis of atopic dermatitis involving at least 10% BSA (exceptions allowed) AND has had inadequate response or intolerance to one topical calcineurin inhibitor AND to one high-potency topical corticosteroid AND has had inadequate response or intolerance to listed biologics (per policy) AND has had inadequate response or intolerance to one traditional systemic therapy (e.g., methotrexate, azathioprine, cyclosporine, mycophenolate mofetil). Exception: if patient already tried listed biologics, trial of a traditional systemic agent is not required. Medication prescribed by or in consultation with a specialist.

Opzelura (ruxolitinib) topical: Individual is aged 12 years or older AND is not immunocompromised AND has had an inadequate response or intolerance to one topical corticosteroid (exception for face/genital) AND has had an inadequate response or intolerance to one topical calcineurin inhibitor.

Use for vitiligo is considered cosmetic and not covered.

Rinvoq (upadacitinib) oral: Individual is aged 12 years or older AND has a diagnosis of atopic dermatitis involving at least 10% BSA (exceptions allowed) AND has had inadequate response or intolerance to one topical calcineurin inhibitor AND to one high-potency topical corticosteroid AND has had inadequate response or intolerance to one traditional systemic therapy (examples listed). Exception: individuals who already tried certain biologics (lebrikizumab or nemolizumab) are not required to step back to a traditional systemic agent. Medication prescribed by or in consultation with a specialist.

Eucrisa (crisaborole) topical: Individual is aged 3 months or older AND has had an inadequate response or intolerance to one topical corticosteroid medication (exception for face/genital) AND for individuals aged 2 years and older, has had an inadequate response or intolerance to one topical calcineurin inhibitor.

Zoryve (roflumilast) 0.15% cream topical: Individual is aged 6 years or older AND has had an inadequate response or intolerance to one topical corticosteroid (exception for face/genital) AND has had an inadequate response or intolerance to one topical calcineurin inhibitor (e.g., pimecrolimus or tacrolimus).

Systemic and biologic therapy initiation

Coverage of systemic/biologic therapies when ALL of the following trial-aligned criteria are met:

Coverage criteria for systemic/biologic therapy: 1) Diagnosis of moderate-to-severe atopic dermatitis as defined by validated scales (e.g., IGA 3-4, EASI >=16, BSA >=10%, or PP-NRS >=4). 2) Inadequate response to optimized topical therapy (skin care, emollients, topical corticosteroids or topical calcineurin inhibitors) or topical therapy medically inadvisable. 3) Documentation of prior systemic therapy exposure or reason systemic therapy is indicated when applicable (includes prior traditional systemic agents or prior biologics/JAKs as specified per agent). 4) Baseline objective severity measures provided in the medical record (e.g., IGA, EASI, BSA, PP-NRS).

Derived from phase 3 trial inclusion criteria and guideline-recommended stepwise care; prior authorization required and documentation should be submitted.

Topical JAK inhibitor (ruxolitinib) criteria

Topical JAK inhibitor (ruxolitinib cream) coverage considerations:

Ruxolitinib topical coverage: 1) Individual is aged 12 years or older and is not immunocompromised. 2) Has had an inadequate response or intolerance to one topical corticosteroid (exception may be granted for face or genital involvement) AND an inadequate response or intolerance to one topical calcineurin inhibitor. 3) Use is intended for short-term, non-continuous topical treatment as studied; clinical trial evidence of efficacy exists primarily up to 8 weeks. 4) Document prior topical treatments, target sites, and rationale for ongoing use beyond studied durations if requesting continuation.

Use for vitiligo is considered cosmetic and not covered; long-term efficacy and use in sensitive areas or children remain to be established.

This policy defines coverage for pharmacologic therapies for atopic dermatitis and excludes uses that are cosmetic or not addressed here. Use of Opzelura (ruxolitinib) for vitiligo is considered cosmetic and is not covered. Additionally, medications or indications not specifically outlined in this policy are considered investigational and may be denied or managed as not medically necessary. Prior authorization and documentation requirements described elsewhere in the policy apply to covered uses and to any non-formulary exception reviews, which may be approved for up to 12 months when criteria are met.

Evidence for topical ruxolitinib (Opzelura) shows benefit in mild-to-moderate atopic dermatitis in the studied population, but clinical trials of the 1.5% cream were limited to an 8-week double-blind period with ongoing open-label extensions. Long-term efficacy remains to be established. Efficacy in sensitive areas (for example, face or genitalia), in younger children, and in routine combination with other topicals or systemic therapies has not been established and should be considered an evidence gap when assessing medical necessity.

Opzelura (ruxolitinib) for vitiligo is expressly considered cosmetic and is not covered under this policy. Requests for ruxolitinib to treat vitiligo should be denied as noncovered cosmetic use.

Any use of the drugs listed in this policy that is not specifically addressed in the coverage criteria is considered not medically necessary or investigational. Providers should include supporting clinical rationale and documentation when requesting coverage for indications outside the policy; absent such evidence, these requests may be denied.

Because randomized double-blind evidence for ruxolitinib cream is limited to the 8-week trial period, use of topical ruxolitinib beyond that studied duration lacks strong double-blind evidence. Continuation or long-term use should be supported by extension-study data or adequate clinical documentation demonstrating sustained benefit; otherwise, ongoing therapy beyond the studied period may be considered not medically necessary.

This policy reiterates that ruxolitinib for vitiligo is considered a cosmetic indication and is not covered. Such requests should be adjudicated as excluded cosmetic treatments per the policy language and history.

Coding and Measurable Criteria

HCPCS codesHCPCS

J3590

Unclassified biologics (use to report: Adbry)

Body surface area (BSA) thresholds used in this policy

BSA threshold used for systemic/biologic agents>= 10% body surface area (BSA)

Exceptions to BSA requirementException may be granted for extensive recalcitrant facial involvement, pustular hands/feet, or genital involvement interfering with sexual function

Agents referencing the >=10% BSA thresholdAdbry (tralokinumab), Ebglyss (lebrikizumab), Nemluvio (nemolizumab), Cibinqo (abrocitinib), Rinvoq (upadacitinib)

Severity and enrollment thresholds used in trials

Investigator's Global Assessment (IGA)Trial enrollment/severity commonly required IGA score of 3–4 (moderate–severe)

Eczema Area and Severity Index (EASI)

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior Authorization and Coding

Prior authorization is required for all listed prescription therapies for atopic dermatitis. Drug-specific prior authorization criteria must be met and documented. For Adbry (tralokinumab‑Idrm) report administration using HCPCS J3590 (Unclassified biologics) when applicable.

Prior authorization required per drug-specific criteria
Use HCPCS J3590 to report Adbry when an unclassified biologic code is needed

Documentation Required

Objective Disease Severity and Prior Treatment Required

Document objective measures of disease severity and prior treatment failures or intolerances when requesting coverage. Confirm the diagnosis of atopic dermatitis and provide validated severity scale scores (e.g., IGA, EASI, BSA, PP‑NRS) and body surface area involvement when applicable.

Provide baseline validated scores (IGA, EASI, PP‑NRS) and BSA involvement

Initial Therapy Requirements by Agent

Initial therapy requirements

Agent-specific initiation requirements (grouped):

General topical/systemic initiation patterns: Most topical and systemic agents require prior inadequate response or intolerance to at least one topical corticosteroid and one topical calcineurin inhibitor; some systemic agents require prior trial of traditional systemic therapies or prior biologic therapies as specified in individual agent criteria. Medication should be prescribed by or in consultation with an allergist, immunologist, or dermatologist when specified.

Exceptions for face/genital involvement and step-back requirements for traditional systemics are described per agent.

Age and BSA thresholds: Many systemic and biologic agents require the individual to be aged 12 years or older and to have atopic dermatitis involving at least 10% BSA, with listed exceptions for specific anatomic or clinical presentations.

Crisaborole (Eucrisa) initiation

Topical nonsteroidal therapy initiation specifics:

Re-authorization and Continuation Requirements

Re-authorization

Re-authorization general: May be approved for up to 12 months as long as drug-specific coverage criteria are met and chart notes document continued positive clinical response to therapy. Submission of office visit notes documenting diagnosis, relevant history, physical evaluation, medication history, and baseline and follow-up disease severity measures is required.

Non-formulary exception reviews and other authorizations may be approved up to 12 months.

Continuation therapy for IL-13 agents

Continuation criteria for IL-13 biologics (e.g., tralokinumab, lebrikizumab):

Continuation therapy: Clinical benefit demonstrated (for example, maintained IGA 0/1 or EASI-75 improvements) AND tolerability to the agent. Evidence from extension phases supports maintenance dosing as per product labeling. Documentation of objective improvement and tolerability must be provided for continued coverage.

Based on phase 3 trials with rerandomization and maintenance follow-up; prior authorization and documentation of baseline and follow-up severity measures recommended.

Step Therapy Expectations and Required Trials

Step requirement	Details / examples
Prior inadequate response or intolerance to topical agents
Most agents require inadequate response or intolerance to one topical corticosteroid medication (exceptions may be granted for face or genital involvement) AND one topical calcineurin inhibitor (e.g., pimecrolimus or tacrolimus). Specific agents list age thresholds and additional documentation requirements.

Step	What is expected / Rationale
Basic skin care and emollients (initial)
Avoidance of triggers, regular moisturization, and optimized basic skin care are expected before topical corticosteroids per guideline-recommended stepwise approach.
Topical therapy (next)
Use of topical corticosteroids and topical calcineurin inhibitors; many agents require documented inadequate response or intolerance to at least one topical corticosteroid and one topical calcineurin inhibitor prior to escalation.
Systemic or biologic therapy (advanced)
For moderate-to-severe disease (e.g., IGA 3-4, EASI ≥16, BSA ≥10% or PP‑NRS ≥4), systemic biologics or JAK inhibitors may be considered when prior topical therapy failed and documentation of disease severity and prior treatments is provided. Some systemic agents additionally require prior traditional systemic therapy or prior biologic trials as specified in agent-specific criteria.

Required prior biologic/JAK trial(s)	Policy detail / exceptions
Trial/failure of listed biologics or JAK inhibitors (example for Cibinqo)
Cibinqo (abrocitinib) requires inadequate response or intolerance to tralokinumab (Adbry), dupilumab (Dupixent), lebrikizumab (Ebglyss), or upadacitinib (Rinvoq) as a step prior to coverage. Documentation of inadequate response or intolerance to the listed agents is required.
Allowance for exception when Ebglyss or Nemluvio tried
If the individual has already tried Ebglyss (lebrikizumab) or Nemluvio (nemolizumab), the policy clarifies that the individual is not required to 'step back' and try a traditional systemic agent prior to coverage; an exception to the traditional systemic therapy requirement may be granted.

Benefit Routing and Site-of-Care Notes

Billing Rule

Adbry managed through pharmacy and medical benefit (infusion/clinic considerations)

Adbry (tralokinumab) may be managed through either the pharmacy or medical benefit; coordinate benefit routing and billing accordingly for infusion/clinic or pharmacy-dispensed administration.

Confirm whether the claim should be billed through the medical benefit (clinic/infusion) or pharmacy benefit based on setting.
Use HCPCS coding guidance (J3590) when appropriate for Adbry reporting.

Billing Rule

Most listed drugs are managed through the pharmacy benefit

Most listed topical, injectable, and oral agents (including Cibinqo, Ebglyss, Eucrisa, Nemluvio, Opzelura, Rinvoq, Vtama, Zoryve) are managed through the pharmacy benefit and should be billed accordingly.

Submit pharmacy benefit claims for agents identified as pharmacy-managed in the policy.

Definitions and Drug Summaries

Atopic dermatitis (AD) — definition

Concise definitionAtopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition characterized by pruritus and eczematous lesions with periodic flares, often associated with impaired skin barrier and allergic sensitization.

Typical symptomsItchy, red, flaky or weeping/oozing rashes and plaques; may be triggered by heat, irritants, foods, or stress

Associated immune featuresAssociated with inappropriate activation of Th2 and ILC2 cells and increased type 2 cytokines (IL‑13, IL‑4)

Topical corticosteroid potency groups — classification and representative agents

Potency classification (US system)Groups range from super‑high (group 1) to lower potencies; selection guided by clinical site and age.

Representative super‑high / group 1 agents

Clinical Background

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease characterized by pruritus and eczematous lesions. It can cause significant morbidity and has a substantial population burden. Initial management emphasizes trigger avoidance, good skin care, regular emollient use, and topical therapies. When topical measures are inadequate for moderate-to-severe disease, this policy outlines stepwise pharmacologic options—including topical nonsteroidal agents, topical corticosteroids and calcineurin inhibitors, topical JAK inhibitors, systemic JAK inhibitors, and biologic therapies—each with agent-specific age, severity, prior-treatment, and documentation requirements.

OpenPayer

Pharmacologic Treatment of Atopic Dermatitis